Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines (RVMD) has 5 years of Current Deferred Revenue data on record, last reported at $1.4 million in Q1 2023.

  • For Q1 2023, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million; the TTM value through Mar 2023 reached $1.4 million, down 87.46%, while the annual FY2022 figure was $4.5 million, 63.92% down from the prior year.
  • Current Deferred Revenue reached $1.4 million in Q1 2023 per RVMD's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $17.1 million in Q4 2019 and bottomed at $1.4 million in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $11.0 million, with a median of $11.8 million recorded in 2020.
  • Peak YoY movement for Current Deferred Revenue: rose 16.18% in 2022, then crashed 87.46% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $17.1 million in 2019, then decreased by 29.27% to $12.1 million in 2020, then grew by 2.04% to $12.4 million in 2021, then crashed by 63.92% to $4.5 million in 2022, then crashed by 67.84% to $1.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $1.4 million in Q1 2023, $4.5 million in Q4 2022, and $9.7 million in Q3 2022.